Compare · CRXT vs LLY
CRXT vs LLY
Side-by-side comparison of Clarus Therapeutics Holdings Inc. (CRXT) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRXT and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.27T.
- LLY has hit the wire 45 times in the past 4 weeks while CRXT has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 3 for CRXT).
- Company
- Clarus Therapeutics Holdings Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.27T
- 1M return
- -
- +6.34%
- 1Y return
- -
- +29.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 45
- Recent ratings
- 3
- 25
Clarus Therapeutics Holdings Inc.
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CRXT
- SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events
- SEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- SEC Form POS AM filed by Clarus Therapeutics Holdings Inc.
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)
- Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest LLY
- Gold, Silver and Crude Slide Hard as Volatility Jumps on the Week
- Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)
- Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)
- Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)
- Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)
- Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)
- Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)
- Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)
- Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)
- Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)